Pfizer Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Pfizer Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- New York
- Headquarters state / province
- New York
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- PFE
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0000078003
- EIN
- 13-5315170
Board of directors
-
Albert Bourla · Director · Chairman & CEOSince 2023
-
Cyrus Taraporevala · DirectorSince 2024
-
Dan R. Littman · DirectorSince 2023
-
Helen Hobbs · DirectorSince 2023
-
James C. Smith · DirectorSince 2023
-
James Quincey · DirectorSince 2023
-
Johnson Suzanne M. Nora · DirectorSince 2023
-
Joseph Echevarria · DirectorSince 2023
-
Mortimer J. Buckley · DirectorSince 2024
-
Ronald E. Blaylock · DirectorSince 2023
-
Scott Gottlieb · DirectorSince 2023
-
Shantanu Narayen · DirectorSince 2023
-
Susan Desmond-Hellmann · DirectorSince 2023
-
Susan Hockfield · DirectorSince 2023
Chief executives
Albert Bourla
· Chairman & CEO
Dates unknown
Director election results
Annual meeting of April 23, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
82.7%
-
92.3%
-
92.6%
-
93.5%
-
95.4%
-
96.0%
-
96.0%
-
96.3%
-
97.1%
-
97.4%
-
97.8%
Board connections
7 of this board's directors also sit on 12 other boards.
- via Shantanu Narayen
- via Ronald E. Blaylock
- via Scott Gottlieb
- via Johnson Suzanne M. Nora
- via Johnson Suzanne M. Nora
- via Scott Gottlieb
- via Joseph Echevarria
- via Mortimer J. Buckley
- via James Quincey
- via Scott Gottlieb
- via Joseph Echevarria
- via Ronald E. Blaylock
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $2,960,110
- 3 purchases by 3 insiders
- Sold, last 12 months
- $134,661
- 2 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 12, 2026 | Albert Bourla Director, Officer (Chairman & CEO) | Open-market purchase | +38,000 | $26.34 | $1,000,920 |
| Aug 5, 2026 | Ronald E. Blaylock Director | Open-market purchase | +39,231 | $25.46 | $998,821 |
| Aug 5, 2026 | Mortimer J. Buckley Director | Open-market purchase | +37,632 | $25.52 | $960,369 |
| Aug 5, 2026 | DAMICO JENNIFER B. Officer (SVP & Controller) | Open-market sale | −3,278 | $25.40 | $83,261 |
| Jun 9, 2026 | DAMICO JENNIFER B. Officer (SVP & Controller) | Open-market sale | −2,000 | $25.70 | $51,400 |
| Mar 4, 2026 | DAMICO JENNIFER B. Officer (SVP & Controller) | Shares withheld for tax | −826 | $26.62 | $21,988 |
| Mar 3, 2026 | DAMICO JENNIFER B. Officer (SVP & Controller) | Grant or award | +16,311 | — | — |
| Mar 3, 2026 | DAMICO JENNIFER B. Officer (SVP & Controller) | Grant or award | +5,408 | — | — |
| Feb 27, 2026 | DAMICO JENNIFER B. Officer (SVP & Controller) | Shares withheld for tax | −655 | $27.65 | $18,111 |
| Feb 26, 2026 | McDermott Michael Officer (Executive Vice President) | Shares withheld for tax | −3,503 | $27.10 | $94,931 |
| Feb 25, 2026 | SAHNI PAYAL Officer (Executive Vice President) | Option exercise | +56,888 | $33.82 | $1,923,952 |
| Feb 25, 2026 | LANKLER DOUGLAS M Officer (Executive Vice President) | Option exercise | +122,907 | $33.82 | $4,156,715 |
| Feb 25, 2026 | DAMICO JENNIFER B. Officer (SVP & Controller) | Option exercise | +17,558 | $33.82 | $593,812 |
| Feb 25, 2026 | Albert Bourla Director, Officer (Chairman & CEO) | Option exercise | +491,626 | $33.82 | $16,626,791 |
| Feb 25, 2026 | Lidia Fonseca Officer (Executive Vice President) | Option exercise | +56,888 | $33.82 | $1,923,952 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.